INTEGRATING LONGEVITY SCIENCE INTO POST-PROCEDURE PRACTICE
- Mar 2026
- 5min (reading time)
At IMCAS Paris, the Vichy symposium translated longevity science into clinical practice by highlighting Dercos Aminexil Clinical R.E.G.E.N. as a post‑procedure dermocosmetic support. Natalia Kovylkina (MD, dermatologist and Global Vichy Medical Relations Director) discussed how to integrate dermocosmetics into hair‑procedure routines to improve the patient experience.
In a controlled clinical study versus topical minoxidil 2% in 100+ patients, the R.E.G.E.N. Booster (based on Aminexil Longevity Technology) showed comparable efficacy in reducing hair loss, with better cosmetic acceptability and tolerance—two factors strongly associated with long‑term adherence. A practical advantage is dosing: once daily versus the typical twice‑daily minoxidil regimen, supporting compliance without loss of performance.
Real‑world case investigations with Dr. Paulo Müller evaluated use after scalp mesotherapy. Interim results (final data pending) indicate better tolerance in the combination group (oedema, pruritus, pain, scalp comfort), with imaging suggesting improved fibre thickness and coverage. Ongoing hair‑transplant studies (FUE plus serum from week 2) will assess recovery and graft optimization at 1, 6 and 9 months; early observations report excellent tolerance and adherence.
In a controlled clinical study versus topical minoxidil 2% in 100+ patients, the R.E.G.E.N. Booster (based on Aminexil Longevity Technology) showed comparable efficacy in reducing hair loss, with better cosmetic acceptability and tolerance—two factors strongly associated with long‑term adherence. A practical advantage is dosing: once daily versus the typical twice‑daily minoxidil regimen, supporting compliance without loss of performance.
Real‑world case investigations with Dr. Paulo Müller evaluated use after scalp mesotherapy. Interim results (final data pending) indicate better tolerance in the combination group (oedema, pruritus, pain, scalp comfort), with imaging suggesting improved fibre thickness and coverage. Ongoing hair‑transplant studies (FUE plus serum from week 2) will assess recovery and graft optimization at 1, 6 and 9 months; early observations report excellent tolerance and adherence.